Business Context and Reporting Period
Company: Penumbra, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 12, 2019
Event Date: March 18, 2019 (FDA Clearance)
Business Context: The filing discloses a regulatory milestone regarding the Company's expansion into rehabilitation technology.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding a regulatory event. It does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics.
Material Changes
The material change reported is the receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for the REAL Immersive System. This system is an immersive virtual reality and display platform designed to interactively display and track upper-extremity rehabilitation exercises for adult patients. The exercises utilize virtual environments and full presence tracked avatars for visual feedback and are intended for use in a seated position within a clinical environment under the supervision of a trained medical professional.
Guidance, Outlook, and Risks
Management Commentary: The Company announced the FDA clearance during an investor call on April 12, 2019.
Guidance: No financial guidance or forward-looking revenue projections were provided in this specific filing.
Risks and Contingencies: The filing notes that the information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not an admission of materiality under Regulation FD.
Investor Verification Checklist
- Verify the commercial launch timeline and market availability of the REAL Immersive System.
- Assess the potential revenue contribution of the new virtual reality product line relative to Penumbra's core neurovascular business.
- Review subsequent filings for any updates on the adoption rate of the REAL Immersive System in clinical environments.
- Confirm if the FDA clearance includes any specific limitations or post-market surveillance requirements.